Tharimmune Announces Dosing Of First Patient In Phase 1 Clinical Trial Of TH104, Its Lead Candidate For Pruritus In Primary Biliary Cholangitis
Tharimmune Announces Dosing Of First Patient In Phase 1 Clinical Trial Of TH104, Its Lead Candidate For Pruritus In Primary Biliary Cholangitis
Tharimmune 宣佈在 TH104 的 1 期臨床試驗中爲首位患者服用劑量，該試驗是其治療原發性膽源性膽管炎瘙癢的主要候選藥物
Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104
第一位患者的 1 期臨床試驗劑量已完成；主要目標是評估 TH104 的安全性/耐受性和絕對生物利用度
Phase 1 study expected to be completed in 1Q24 with topline readout in 2Q24
第一階段研究預計將於24年第一季度完成，頂線讀數將於24年第二季度公佈
Company fully funded into 2025 with full readouts of Phase 1 and 2 in moderate-to-severe chronic pruritus in PBC expected in 4Q24/1Q25
公司在 2025 年獲得全額資金，預計在 25 年第 4 季度/第 1 季度全面公佈中國人民銀行中度至重度慢性瘙癢症的第一階段和第二階段
BRIDGEWATER, NJ / ACCESSWIRE / February 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the first patient dosed in the Company's Phase 1 clinical trial with TH104, utilizing a proprietary oral thin film. TH104 is a proprietary transmucosal...
新澤西州布里奇沃特/ACCESSWIRE/2024年2月5日/Tharimmune, Inc.（納斯達...
登入免費觀看全文
登入/註冊